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Introduction: Observational studies, linking characteristics of breast cancer with
hormone replacement therapy (HRT), have given mixed results. Overall, most
report favourable stage and prognostic characteristics, with a predominance of
receptor-positive breast cancers. In the ‘‘World Health Initiative’’ randomised
trial, breast cancers that occurred among women using combined HRT, did not
have such favourable characteristics [2]. The ‘‘Million Women Study’’ conﬁrmed
that current use of HRT is associated with an increased risk of invasive breast
cancer. This eﬀect is substantially greater for combined HRT [1]. Kerlikowske
and colleagues [3] speciﬁcally looked at prognostic characteristics of breast
cancer among HRT-users in a screened population. This study also demon-
strates an increased risk for women using combined HRT for a long duration.
The risk was increased both for tumours with favourable and unfavourable
prognostic characteristics.
We looked at the eﬀect of HRT on tumour characteristics, and examined
whether mode of detection aﬀected this, by comparing tumour characteristics of
screen-detected and palpable tumours, both in HRT-users and non-users.
Patients and methods: During one year, from September 2002 onwards, we
prospectively collected demographic data in all postmenopausal women who
underwent primary surgery for invasive breast cancer (N=362). Exclusion
criteria were ‘‘ever-use’’ of HRT (>1 year before diagnosis, N=31) and bilateral
breast cancer (N=4). For this analysis, 327 women were eligible, of whom 42.8%
were using HRT. We looked at the eﬀect of HRT and compared mean values for
age, mode of detection, histological type, size, grade, Nottingham Prognostic
Index (NPI), nodal and receptor status.
Results: We looked at the two subgroups: HRT-users (N=144) versus non-users
(N=183), to evaluate the eﬀect of HRT use on tumour characteristics.
HRT-users were signiﬁcantly younger when diagnosed with breast cancer (58.8
versus 67.3 years, P<0.001), had more screen-detected cancers (56.3% versus
38.8%, P=0.002) and a lower NPI (3.86 versus 4.33, P=0.001). HRT-users had
signiﬁcantly more grade I tumours (23.8% versus 11.5%), and less grade III
tumours (28.7% versus 45.6%, P=0.001).
There was no signiﬁcant diﬀerence in the percentage of invasive lobular
carcinoma (±14%, P=0.923), size of the lesions (25.28 versus 27.36 mm,
P=0.382), nodal status (25% versus 32.2%, P=0.177) or receptor status.
To evaluate the eﬀect of HRT, we looked at the two subgroups, palpable versus
screen-detected tumours, and stratiﬁed for HRT use.
In the subgroup of palpable tumours (N=175; HRT-users, N=63), we found that
HRT-users were younger (59.3 versus 69.8 years, P<0.001), had a lower NPI 4.23
versus 4.76, P=0.006) and more grade I (22.2% versus 5.4%) and less grade III
lesions (38.1% versus 56.3%, P=0.002), but had tumours with the same size
(28.98 versus 33.01 mm, P=0.474) and had the same nodal status (36.5% N
positive versus 43.8%, P=0.424).
In the subgroup of screen-detected tumours (N=152; HRT-users, N=81), we
found that HRT-users were younger (58.1 versus 62.9 years, P<0.001), but the
tumours had the same size (22.45 versus 18.46 mm, P=0.261), NPI (3.58 versus
3.63, P=0.775), grade (25.0% versus 21.4% grade I, 53.8% versus 50.0% grade II,
21.3% versus 28.6% grade III, P=0.572) and nodal status (16% N positive versus
14.1%, P=0.822).
To evaluate the eﬀect of screening, we looked at the two subgroups, HRT-users
versus never-users of HRT, and stratiﬁed for mode of detection. In the subgroup
of HRT users (N=144), we found that screen-detected breast cancers (N=81) had
a lower NPI (3.58 versus 4.23, P=0.004) and less positive lymph nodes (16%
versus 36.5%, P=0.006), but the tumours had the same size (22.45 versus 28.98
mm, P=0.104), grade (25.0% versus 22.2% grade I, 53.8% versus 39.7% grade II,
21.3% versus 38.1% grade III, P=0.079) and they were diagnosed at the same age
(58.1 versus 59.3 years, P=0.320).
In the subgroup of non-users (N=183), we found that screen-detected breast
cancers (N=71) were smaller (18.46 versus 33.01 mm, P<0.001), had a lower NPI
(3.63 versus 4.76, P<0.001) and that patients were younger (62.9 versus 69.8
years, P<0.001), had more grade I (21.4% versus 5.4%), less grade III lesions
(28.6% versus 56.3%, P<0.001) and less lymph node-positive tumours (14.1%
versus 43.8%, P<0.001).
Conclusions: HRT-users are younger when diagnosed with an invasive breast
cancer, and the lesion is more likely to be screen-detected, with a lower NPI and
grade. The eﬀect of HRT is most obvious for breast cancers detected by self-
examination: only the palpable, but not the screen-detected breast cancers have
better prognostic tumour characteristics in HRT-users. Mode of detection may
explain inconsistencies in the literature regarding the eﬀect of HRT on tumour
characteristics of operable breast cancers and is an important variable to be
taken into account.
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